ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report)'s share price traded up 8.8% on Monday . The stock traded as high as $21.18 and last traded at $21.11. 4,282,141 shares were traded during trading, an increase of 20% from the average session volume of 3,567,260 shares. The stock had previously closed at $19.40.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.
Check Out Our Latest Analysis on ADMA
ADMA Biologics Stock Performance
The company's 50-day moving average price is $18.26 and its two-hundred day moving average price is $18.23. The company has a market cap of $5.04 billion, a P/E ratio of 76.11 and a beta of 0.53. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.
Institutional Investors Weigh In On ADMA Biologics
A number of institutional investors and hedge funds have recently modified their holdings of ADMA. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of ADMA Biologics by 1.3% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock valued at $865,000 after acquiring an additional 645 shares during the period. Oregon Public Employees Retirement Fund grew its position in ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock worth $954,000 after acquiring an additional 700 shares in the last quarter. Summit Investment Advisors Inc. raised its holdings in ADMA Biologics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock valued at $404,000 after buying an additional 746 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in ADMA Biologics by 2.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock worth $614,000 after purchasing an additional 751 shares during the last quarter. Finally, Maryland State Retirement & Pension System boosted its holdings in shares of ADMA Biologics by 1.1% during the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock worth $1,365,000 after buying an additional 897 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.
ADMA Biologics Company Profile
(
Get Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
